Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry tracks how ATTR-CM patients are treated in daily practice

NCT ID NCT06651073

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This study is a disease registry that collects information from routine medical care of about 350 adults diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) in Taiwan, Hong Kong, and Malaysia. Researchers will look at patient characteristics, treatments received, and how the disease progresses over time. No new treatments or tests are given—participants continue their usual care. The goal is to better understand real-world management of ATTR-CM.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

350 people

The number who actually took part.

Started

Oct 2024

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The patient population will include all adult patients with a confirmed diagnosis of ATTR-CM after 01 June 2019 and who meet eligibility criteria. The index date of each patient will be the date of the first documented ATTR-CM diagnosis. The observation period for each patient will range from the index date to whichever occurs first of death, patient withdrawal of consent, loss to follow-up, or end of data collection. The end of data collection (ie, the end of study) is planned for 12 months after the end of the enrollment period.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Waivers of informed consent for deceased patients will be pursued if permitted by local regulation 2. Patients aged ≥18 years at first ATTR-CM diagnosis 3. Patients with confirmed diagnosis of ATTR-CM after 01 June 2019 Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Transthyretin amyloid cardiopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Transthyretin amyloid cardiopathy

Contacts and locations

Locations

  • Chang Gung Memorial Hospital, Linkou

    Gueishan Township, Taoyuan, 333, Taiwan

  • Chi Mei Medical Center

    Tainan, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan R O C, 40447, Taiwan

  • Far Eastern Memorial Hospital

    New Taipei City, 220, Taiwan

  • Hospital Serdang

    Kuala Selangor, Malaysia

  • Institut Jantung Negara

    Kuala Lumpur, Malaysia

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, 833, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 807, Taiwan

  • MacKay Memorial Hospital

    Taipei, 10449, Taiwan

  • National Taiwan University

    Taipei, 100225, Taiwan

  • Prince of Wales Hospital

    Shatin, Hong Kong

  • Princess Margaret Hospital

    Kwai Chung, Hong Kong

  • Queen Elizabeth Hospital

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    Pok Fu Lam, Hong Kong

  • Sarawak Heart Centre

    Sarawak, Malaysia

  • Taichung Veterans General Hospital

    Taichung, Taipei, 40705, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.